Harvard Catalyst recently named MDG Boston volunteer and board member, llsa Webeck, to be 2022 Course Director for the Harvard Catalyst TRANSCEND (TRANSforming Care with Emerging, Novel Devices) program.

Harvard Catalyst, Harvard University’s Clinical & Translational Science Center, works with Harvard University’s schools and affiliate academic healthcare centers to build and grow an environment focused on team science – where discoveries are rapidly and efficiently translated to improve human health.  “I was thrilled to be asked to lead the TRANSCEND program this year.  As a former speaker for the program, I saw the high-quality programming and benefit that Harvard Catalyst brings to our community,” said Ilsa Webeck, Managing Director and Founder of MedTech Strategies.  “TRANSCEND aligns well with the work we are doing at MDG Boston, providing educational and networking opportunities for professionals in the MedTech space.”

TRANSforming Care with Emerging, Novel Devices (TRANSCEND) explores the current climate for the development of class II and class III medical devices through hybrid programming, providing entrepreneurial attendees an opportunity to hear directly from experts in the field and discuss the critical aspects and challenges of device development.  The course will culminate in a pitch competition where participants will have the opportunity to earn services, consultation, and educational offerings that are valued at over $15,000.  Applications are due by March 30th.